ACXP

Acurx is a pre-revenue, clinical-stage biopharma whose entire value rests on one drug — ibezapolstat for C. difficile infection — still in Phase 2. The MD&A and Risk Factors say the quiet part plainly: the company is 'reliant on the success of our lead product candidate,' warns it 'may need substantial additional funding,' and concedes it 'may never achieve or maintain profitability.' There is no product, no revenue in any year (FY2021–FY2025), and the business intends to 'partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization' — i.e. it cannot fund the finish line itself.

The balance sheet frames the clock. FY2025 cash is just $7.56M against operating cash burn of -$6.79M — roughly one year of runway before a raise is needed. The headline 'improvements' are misleading: the net loss narrowed to -$7.97M (from -$14.1M) largely because R&D was slashed 66.1% to $1.83M, which for a clinical-stage company means less development, not more progress. Stockholders' equity 'grew 756.5%' to $5.27M and shares outstanding 'fell 87%' to 2.86M — the share collapse is a reverse split, and the -$5.32 diluted EPS and -151.2% ROE reflect a tiny, deeply loss-making shell with a -$75.3M accumulated deficit.